A detailed history of Corton Capital Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Corton Capital Inc. holds 62,491 shares of RXRX stock, worth $431,812. This represents 0.21% of its overall portfolio holdings.

Number of Shares
62,491
Previous 14,092 343.45%
Holding current value
$431,812
Previous $105,000 291.43%
% of portfolio
0.21%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.92 - $8.6 $286,522 - $416,231
48,399 Added 343.45%
62,491 $411,000
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $103,576 - $141,624
14,092 New
14,092 $105,000
Q2 2023

Aug 14, 2023

SELL
$4.56 - $9.94 $58,641 - $127,828
-12,860 Reduced 39.37%
19,801 $147,000
Q1 2023

May 15, 2023

BUY
$6.42 - $9.64 $209,683 - $314,852
32,661 New
32,661 $217,000
Q2 2022

Aug 15, 2022

BUY
$5.04 - $9.26 $83,653 - $153,697
16,598 New
16,598 $135,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.25B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Corton Capital Inc. Portfolio

Follow Corton Capital Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

News

Stay updated on Corton Capital Inc. with notifications on news.